文献速递MDS 与骨髓增殖性肿瘤

儿童及年轻成人骨髓增殖性肿瘤的真实世界研究:识别风险与未满足需求

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
PubMed 文献 · Blood Adv · 2022-01-01

该研究纳入15个国家38个中心的444例25岁前确诊的骨髓增殖性肿瘤患者,中位随访9.7年。结果显示血栓事件和疾病转化率高于既往文献预期,JAK2V617F突变和高黏滞症状为血栓风险因素,脾肿大为ET转化的新风险因素,现有预后评分无法预测年轻ET或PV患者生存。

要点

  • 诊断时49例(11.1%)有血栓史,随访中新发血栓事件49例(1.16%患者/年), perihepatic静脉血栓最常见(占静脉事件的47.6%)。
  • JAK2V617F突变(P=0.016)和高黏滞症状(视觉障碍、头晕、眩晕、头痛)是血栓风险因素(P=0.040)。
  • 疾病转化48例(10.9%,1.13%患者/年),多转化为骨髓纤维化(7.5%),脾肿大是ET转化的新风险因素(P=0.000)。

核心结论

  • 这是目前最大规模的25岁前诊断的MPN患者真实世界研究,血栓事件和疾病转化率高于既往文献预期。
  • 研究为前瞻性研究、临床试验和制定年轻MPN患者特异性管理的国际协调指南提供了新的可靠信息基础。

研究设计与样本

  • 来自15个国家38个中心的前瞻性连续纳入的25岁前诊断的MPN患者,共444例,中位随访9.7年(范围0-47.8年)。

主要发现

  • 诊断时49例(11.1%)有血栓史;随访中新发血栓事件49例(1.16%患者/年),perihepatic静脉血栓最常见(占静脉事件的47.6%)。
  • 逻辑回归识别JAK2V617F突变(P=0.016)和高黏滞症状(视觉障碍、头晕、眩晕、头痛)为血栓风险因素(P=0.040)。
  • 新发血液学事件44例(9.9%,1.04%患者/年);疾病转化48例(10.9%,1.13%患者/年),通常转化为骨髓纤维化(7.5%),脾肿大是ET转化的新风险因素(P=0.000)。
  • 记录死亡8例(1.8%),其中3例发生在异基因干细胞移植后。
  • 国际ET血栓预后评分和新国际ET血栓预后评分可区分ET患者的血栓风险,两者识别的高危患者中位无血栓生存期均为28.5年;现有评分均无法预测年轻ET或PV患者的生存。

关键数值与推荐

  • 诊断时血栓史:49/444例(11.1%)。
  • 新发血栓事件率:1.16%患者/年;perihepatic静脉血栓占静脉事件的47.6%。
  • 新发血液学事件率:1.04%患者/年(44例,9.9%)。
  • 疾病转化率:1.13%患者/年(48例,10.9%);转化为骨髓纤维化7.5%。
  • 死亡8例(1.8%),其中3例在异基因干细胞移植后。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPNs) are uncommon in children/young adults. Here, we present data on unselected patients diagnosed before 25 years of age included from 38 centers in 15 countries. Sequential patients were included. We identified 444 patients, with median follow-up 9.7 years (0-47.8). Forty-nine (11.1%) had a history of thrombosis at diagnosis, 49 new thrombotic events were recorded (1.16% patient per year [pt/y]), perihepatic vein thromboses were most frequent (47.6% venous events), and logistic regression identified JAK2V617F mutation (P = .016) and hyperviscosity symptoms (visual disturbances, dizziness, vertigo, headache) as risk factors (P = .040). New hemorrhagic events occurred in 44 patients (9.9%, 1.04% pt/y). Disease transformation occurred in 48 patients (10.9%, 1.13% pt/y), usually to myelofibrosis (7.5%) with splenomegaly as a novel risk factor for transformation in essential thrombocythemia (ET) (P= .000) in logistical regression. Eight deaths (1.8%) were recorded, 3 after allogeneic stem cell transplantation. Concerning conventional risk scores: International Prognostic Score for Essential Thrombocythemia-Thrombosis and new International Prognostic Score for Essential Thrombocythemia-Thrombosis differentiated ET patients in terms of thrombotic risk. Both scores identified high-risk patients with the same median thrombosis-free survival of 28.5 years. No contemporary scores were able to predict survival for young ET or polycythemia vera patients. Our data represents the largest real-world study of MPN patients age < 25 years at diagnosis. Rates of thrombotic events and transformation were higher than expected compared with the previous literature. Our study provides new and reliable information as a basis for prospective studies, trials, and development of harmonized international guidelines for the specific management of young patients with MPN.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sobas M, Kiladjian JJ, Beauverd Y, et al. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022. PMID: 35802458. doi:10.1182/bloodadvances.2022007201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。